The SPAC is now live with $100M in trust and a 24-month clock. Monitor for any 8-K announcing a definitive business combination agreement — the forward purchase agreement from TCG Crossover Fund III provides a $20M backstop that reduces deal-closing risk. No target has been identified yet, so near-term trading will track SPAC market sentiment and redemption expectations.
Executive Summary
TCGX Acquisition Corp. II (TCXB) has completed its $100 million IPO of 10,000,000 Class A ordinary shares at $10.00 per share, with a concurrent $4.5 million private placement of 450,000 shares to the sponsor. The SPAC has 24 months to complete an initial business combination, targeting healthcare/life sciences companies, and has a $20 million forward purchase agreement commitment from TCG Crossover Fund III. The offering is now priced and closed — the dilution is certain.
Key Financial Metrics
Key Facts
- IPO of 10,000,000 Class A ordinary shares at $10.00 per share, raising $100,000,000 in gross proceeds
- Concurrent private placement of 450,000 shares to sponsor TCGX Sponsor II, LLC for $4,500,000 ($10.00/share)
- Total shares outstanding post-offering: 12,950,000 (10M public + 2.5M founder + 450K private placement)
- $100,000,000 deposited in trust account ($10.00 per public share)
- Underwriters: Guggenheim Securities (sole book-runner); $4,000,000 total underwriting commissions ($1M upfront + $3M deferred)
- Sponsor holds 2,860,000 shares (22.1%) post-offering; founder shares purchased at ~$0.01/share
- 24-month deadline to complete initial business combination; no warrants issued to public shareholders
- Forward purchase agreement with TCG Crossover Fund III for minimum $20,000,000 (2,000,000 shares at $10.00) at business combination close
- Public shareholders have redemption rights at $10.00 per share upon business combination or liquidation
Financial Impact
$100,000,000 gross IPO proceeds + $4,500,000 private placement = $104,500,000 total; $100,000,000 in trust; ~$2,500,000 working capital outside trust
Risk Factors
- No target identified — risk of liquidation if no deal within 24 months
- Sponsor founder shares purchased at ~$0.01/share create misaligned incentives (22.1% ownership for $4.5M total sponsor investment)
- Public shareholders face immediate dilution: implied value per share of $7.49 vs $10.00 offering price
- Forward purchase agreement subject to investment committee approval — not guaranteed
- Conflicts of interest with affiliated SPAC (TCGX Acquisition Corp.) seeking similar healthcare targets
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (Primary) | 0001193125-26-424217 |
| Document: 0001193125-26-424217-index-headers.html | 0001193125-26-424217 |
| Document: 0001193125-26-424217-index.html | 0001193125-26-424217 |
| Document: 0001193125-26-424217.txt | 0001193125-26-424217 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | SC 13G | $10.27 | awaiting T+20 | — | $10.28 (+0.10%) |
Oct 26, 2026 1d ago | SC 13G | $10.27 | awaiting T+20 | — | $10.28 (+0.10%) |
Oct 23, 2026 4d ago | SC 13G | $10.27 | awaiting T+20 | — | $10.28 (+0.10%) |
Oct 23, 2026 4d ago | SC 13G | $10.27 | awaiting T+20 | — | $10.28 (+0.10%) |
Oct 20, 2026 7d ago | 3 | $10.50 | awaiting T+20 | — | $10.28 (−2.10%) |
Oct 20, 2026 7d ago | 3 | $10.50 | awaiting T+20 | — | $10.28 (−2.10%) |
Oct 19, 2026 8d ago | 8-K | $10.56 | awaiting T+20 | — | $10.28 (−2.65%) |
Oct 16, 2026 11d ago | 424B4 | $10.40 | awaiting T+20 | — | $10.28 (−1.15%) |
Oct 16, 2026 11d ago | EFFECT | $10.86 | awaiting T+20 | — | $10.28 (−5.34%) |
Oct 15, 2026 11d ago | 3 | $10.86 | awaiting T+20 | — | $10.28 (−5.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers